Drug & Supplement Interactions

Antineoplastons + tipranavir

Brand name of tipranavir

  • Aptivus

Medically reviewed by

Also reviewed by the HelloPharmacist Editorial Team

Updated July 2026Details about this page

AI is used only to summarize verified clinical information, never the open internet. Our AI policy

The Bottom Line No Known Interaction

We found no known interaction between Antineoplastons and tipranavir in our sources.

This also applies to Aptivus, a brand name of tipranavir.

Still Worth Knowing

  • Shared side effects: Although there is no interaction, both can cause some of the same side effects. Taken together, those side effects might add up, and a new symptom can be harder to pin on one or the other.
  • Food rule: The label for tipranavir states a food rule worth keeping to.
See the Full Interaction Report

Ask a Question About This Combination

Ask in your own words about taking Antineoplastons with tipranavir. The answer comes from this page’s own records.

Try:

AI answers from this page’s interaction records and our own drug and supplement information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist. How we use AI

Interaction Report

Antineoplastons and tipranavir Interaction Check

No Known Interaction Found

We did not find a documented interaction between tipranavir and Antineoplastons in our sources. This does not guarantee that the combination is completely free of risk — there is often limited research on supplements and herbal products, especially around drug interactions.

How We Checked

Why No Interaction Is Listed for tipranavir

Antineoplastons has no interaction record with any drug in our interaction database, so this rests on missing data, not on a study that found nothing.

Still wondering about combining Antineoplastons and tipranavir? Ask Dr. Brian Staiger, PharmD, BCPS directly ›
Know someone taking this combination? Share

Before You Combine Them

Taking Antineoplastons and tipranavir Together

What to Watch For

Side Effects Antineoplastons and tipranavir Have in Common

9 side effects show up for both Antineoplastons and tipranavir.

  • Each has separately been linked to the effects below. Taken together, they might add up: the same side effect from two sources might be more likely or stronger. No study of the two together says by how much.
  • If one turns up, it can be harder to tell which one is behind it, so tell your pharmacist you take both.
  • One of them is worth acting on rather than waiting out, marked below.
  • Anemia Worth Acting On Additional detail

    Antineoplastons

    Orally and intravenously, decreased bone marrow activity has been reported for patients treated with chemotherapy along with antineoplaston A10 or antineoplaston AS2-1; however, this effect has not been observed for patients treated with these antineoplastons without chemotherapy.

    Intravenously, antineoplastons A10 and AS2-1 have been associated with anemia and lowered white blood cell counts in patients with brain t…

    Source: , the clinical database we license.

    6 references cited
    1. 20101. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.
    2. 25604. Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249. PubMed
    3. 25603. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed
    4. 25611. Burzynski SR, Weaver RA, Janicki T, et al. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1. Integr Cancer Ther 2005;4(2):168-177. PubMed
    5. 99814. Burzynski SR, Janicki TJ, Weaver RA, Burzynski B. Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integr Cancer Ther. 2006 Mar;5(1):40-7. PubMed
    6. 25623. Kumabe T, Tsuda H, Uchida M, et al. Antineoplaston treatment for advanced hepatocellular carcinoma. Oncol Rep 1998;5(6):1363-1367. PubMed

    tipranavir

    Source: tipranavir’s

    It lists this side effect in its Adverse Reactions section.

    Read tipranavir’s label on DailyMed ›
  • Numbness or tingling / Headache Additional detail

    Antineoplastons

    Orally and intravenously, headache, fatigue, sleepiness, ringing in the ears, and numbness have been reported for patients treated with antineoplastons A10 and AS2-1. Dizziness has also been noted for some patients treated with oral antineoplaston A10 or intravenous antineoplaston A3.

    Source: , the clinical database we license.

    6 references cited
    1. 25593. Buckner JC, Malkin MG, Reed E, et al. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 1999;74(2):137-145. PubMed
    2. 25601. Burzynski SR, Conde AB, Peters A, et al. A retrospective study of antineoplastons A10 and AS2-1 in primary brain tumors. Clin Drug Invest 1999;18(1):1-10.
    3. 25603. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed
    4. 25610. Burzynski SR, Weaver RA, Lewy RI, et al. Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report. Drugs R D 2004;5(6):315-326. PubMed
    5. 25620. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.
    6. 20101. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.

    tipranavir

    Source: tipranavir’s

    It lists this side effect in its Adverse Reactions section.

    Read tipranavir’s label on DailyMed ›
  • Fever Additional detail

    Antineoplastons

    Adverse effects to antineoplastons have been reported in several small clinical studies. It is not clear how common these reactions are, or if they occur more frequently than with placebo. Since many patients taking antineoplastons have been diagnosed with serious illnesses, such as advanced cancers, it is not clear if these effects resulted from the illnesses themselves or were caused by antineoplastons.

    Source: , the clinical database we license.

    5 references cited
    1. 20101. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.
    2. 25604. Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249. PubMed
    3. 25620. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.
    4. 25621. Burzynski SR, Kubove E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up. Drugs Exp Clin Res 1987;13 Suppl 1:1-11.
    5. 25603. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed

    Intravenously, fever has been reported in patients receiving 6 months of treatment with A10 (11.3 grams/kg daily) and AS2-1 (0.4 grams/kg daily).

    Source: , the clinical database we license.

    2 references cited
    1. 25603. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed
    2. 25619. Burzynski SR, Burzynski B, Mohabbat MO. Toxicology studies on antineoplaston AS2-1 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:25-35.

    tipranavir

    Source: tipranavir’s

    It lists this side effect in its Adverse Reactions section.

    Read tipranavir’s label on DailyMed ›
  • Stomach pain / Vomiting / Nausea Additional detail

    Antineoplastons

    Orally, nausea, vomiting, upset stomach, abdominal pain, and excessive flatulence has been reported for patients with neoplastic disease treated with antineoplaston A10 100-149 mg/kg/day for up to 149 days.

    Source: , the clinical database we license.

    2 references cited
    1. 20101. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.
    2. 25620. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.

    tipranavir

    Source: tipranavir’s

    It lists this side effect in its Adverse Reactions section.

    Read tipranavir’s label on DailyMed ›
  • Tiredness Additional detail

    Antineoplastons

    Orally and intravenously, antineoplastons AS2-1 and A10 have been associated with peripheral edema. Swelling of joints, muscle and joint pain, muscle contractions in the throat, weakness, and fatigue have been reported for patients treated with antineoplastons A2, AS2-1, AS2-5, and/or A10.

    Source: , the clinical database we license.

    5 references cited
    1. 25604. Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249. PubMed
    2. 25624. Burzynski SR. Toxicology studies on antineoplaston AS2-5 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:17-24.
    3. 25603. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed
    4. 25620. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.
    5. 25621. Burzynski SR, Kubove E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up. Drugs Exp Clin Res 1987;13 Suppl 1:1-11.

    tipranavir

    Source: tipranavir’s

    It lists this side effect in its Adverse Reactions section.

    Read tipranavir’s label on DailyMed ›
  • A skin rash Additional detail

    Antineoplastons

    Intravenously, mild maculopapular allergic-type rash has been noted in patients receiving antineoplaston AS2-1, up to 160 mg/kg daily for up to 2.4 years. During 6 months of intravenous bolus injections of A10 (11.3 grams/kg daily) and AS2-1 (0.4 grams/kg daily), three cases of skin rash were reported for patients with recurrent brain stem glioma.

    Source: , the clinical database we license.

    4 references cited
    1. 25619. Burzynski SR, Burzynski B, Mohabbat MO. Toxicology studies on antineoplaston AS2-1 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:25-35.
    2. 25603. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed
    3. 25623. Kumabe T, Tsuda H, Uchida M, et al. Antineoplaston treatment for advanced hepatocellular carcinoma. Oncol Rep 1998;5(6):1363-1367. PubMed
    4. 25624. Burzynski SR. Toxicology studies on antineoplaston AS2-5 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:17-24.

    tipranavir

    Source: tipranavir’s

    It lists this side effect in its Adverse Reactions section.

    Read tipranavir’s label on DailyMed ›

Reported for Antineoplastons but not commonly for tipranavir: an irregular heartbeat, ringing in the ears, chest pain and stomach upset.

Note: Effects for tipranavir come from the Adverse Reactions section of its FDA label; effects for Antineoplastons come from the Natural Medicines adverse-effect record, quoted above. The two sources word some effects differently, so we match them by meaning.

If You Decide to Take Both
  • Add one new thing at a time, and note the date you started it.
  • A start date turns “I’ve been feeling off” into something a pharmacist can work with.
  • Do not stop a prescribed medicine on your own.
  • Check with your pharmacist or doctor before changing any medicine or supplement, especially if you take several or have an ongoing health condition.
How to Take Them

Some tipranavir Products Have a Food Rule — Antineoplastons Should Not Break It

At least one FDA label for a product containing tipranavir says to take it with food. If you take Antineoplastons on an empty stomach out of habit, keep them separate — and take tipranavir with a meal where the label says to.

This may not be true of your version. Food instructions belong to the product, not the ingredient: two tipranavir products can carry different directions, and extended-release forms often differ from immediate-release ones. The label we read is quoted below — check the directions on your own box or bottle, or ask your pharmacist, for how to take the exact product you were given.

( 2.2 ) APTIVUS taken with ritonavir tablets must be taken with meals ( 2.1 ) APTIVUS capsules must be swallowed whole and must not be opened or chewed ( 2.1 ) Children should be assessed for their ability to swallow capsules before prescribing APTIVUS capsules.

From the Dosage and Administration section of the FDA label we read for tipranavir — where that label names a specific product, the instruction is that product's. Read the label on DailyMed ›

A food rule is not an interaction — it is about how much of the medicine you absorb. The directions that came with your own product, and your pharmacist, outrank anything on this page.

Your Whole Routine

Your Other Medicines and Supplements

Alternatives for the Same Use

Other Supplements for the Same Uses as Antineoplastons, and How They Mix With tipranavir

Choosing a supplement while you take tipranavir? Pick what you use Antineoplastons for to see other options studied for it, and whether each has a documented interaction with tipranavir.

What do you take Antineoplastons for?

For Prostate Cancer

1 of them has a documented interaction with tipranavir: Sulforaphane (moderate).

3 other supplements have at least some evidence of a benefit for prostate cancer. Antineoplastons itself is graded for it.

  • Sulforaphane Graded Moderate
  • Lycopene Graded No Known Interaction
  • Strontium Graded No Known Interaction

For Colorectal Cancer

1 of them has a documented interaction with tipranavir: Turkey Tail Mushroom (minor).

2 other supplements have at least some evidence of a benefit for colorectal cancer. Antineoplastons itself is graded for it.

The grades come from the Natural Medicines database and describe the research so far, not a recommendation, and none of these supplements replaces a prescribed medicine.

Everything Else You Take

See Every Supplement That Interacts With tipranavir

Take other supplements too? 217 supplements have a documented interaction with tipranavir, each explained on its page.

By severity: 3 major, 168 moderate and 46 minor.

The Most Serious There Right Now:

Open the tipranavir interaction pageEvery supplement checked against tipranavir, ranked by severity

Get to Know Each One

About Antineoplastons and tipranavir

Supplement

About Antineoplastons

Antineoplastons are synthetic peptide and amino acid compounds promoted as an alternative cancer treatment, but they are not approved by the FDA and high-quality clinical evidence supporting their effectiveness is lacking. Most studies have been conducted by their developer and have not been independently confirmed. If you are considering them, talk with your oncologist first, and never replace proven cancer treatment with an unproven one.

Full Antineoplastons guide: uses, dosage, safety and every interaction
Safety at a Glance

How Antineoplastons Is Rated

  • Antineoplastons Overall

    Use caution

    Not FDA-approved; effectiveness is unproven and side effects can be serious, especially at high doses.

  • Pregnancy

    Avoid

    There is no reliable safety data, so use during pregnancy should be avoided.

  • Breastfeeding

    Avoid

    Safety while breastfeeding is unknown, so it should be avoided.

Medication

About Tipranavir

Brand name: Aptivus

Aptivus (tipranavir) capsules, taken together with ritonavir, are used with other HIV medicines to treat HIV-1 infection. They are for adults and children weighing 36 kg or more who have already been treated and whose virus is resistant to more than one protease inhibitor.

Tipranavir: uses, dosage and side effects Tipranavir: interactions with other drugs Taking more than these two? Check Antineoplastons and Tipranavir with everything else you take Tipranavir NDC codes and packages

More to Explore

More Pairs and Interactions to Check

Keep Checking

Other Drugs & Antineoplastons

Browse every other medication we’ve checked against Antineoplastons — both the ones with a known interaction and the ones without. Select any drug for the full detail.

0Major
0Moderate
0Minor
2,829No known interaction
No Interaction 2,829 drugs checked — show the list
How Much People Look This Up

Where Antineoplastons and tipranavir Sit Against Everything Else

Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.

Supplement Antineoplastons
Steady interest

#1,285 of 1,458 supplements looked up here in the last 7 days

29 days ago today
Medication tipranavir
Steady interest

#1,560 of 2,830 medications looked up here in the last 7 days

29 days ago today

A rank of lookups on this site, not of how often either one is used. It counts every visit, automated ones included, and identifies no one.

Questions and Sources

Common Questions and Where This Comes From

Pharmacist Counseling Corner

Taking Antineoplastons and tipranavir Together: Common Questions

Can you take Antineoplastons with tipranavir?
We do not list a known interaction between Antineoplastons and tipranavir. That does not guarantee the combination is risk-free, so confirm with your pharmacist or doctor — especially if you take other medications or have a health condition.
Can you take Antineoplastons with Aptivus?
Aptivus is a brand name of tipranavir, so the answer is the same as for tipranavir. We do not list a known interaction between Antineoplastons and tipranavir. Everything on this page applies to Aptivus too.
Do Antineoplastons and tipranavir have any of the same side effects?
Yes — our sources link each of them separately to 9 of the same effects. That is not a documented interaction, but taken together the same side effect from two sources might be more likely or stronger; no study of the two together says by how much. And if one of those effects turns up, it can be harder to tell which one is behind it. They are listed on this page with the source behind each.
Should I take Antineoplastons and tipranavir at the same time of day?
At least one FDA label for a product containing tipranavir says to take it with food. If you take Antineoplastons on an empty stomach out of habit, keep them separate and take tipranavir with a meal where the label says to. Food instructions belong to the product rather than the ingredient — two tipranavir products can differ — so check the directions on your own box. This is about absorption, not an interaction.
Do other supplements studied for prostate cancer interact with tipranavir?
1 of the 3 other supplements the Natural Medicines database grades as having some evidence of a benefit for prostate cancer has a documented interaction with tipranavir: Sulforaphane (moderate). A grade is the research so far, not a recommendation, and no known interaction is not proof of safety; ask your pharmacist before adding one.
Does tipranavir interact with any supplements?
Yes. tipranavir has documented interactions with 217 supplements in our database — Antineoplastons is not one of them. The tipranavir interaction page linked on this page lists every one, ranked by severity.

Written and reviewed by the HelloPharmacist Editorial Team. Our editorial policy

Evidence & Sources

References Cited on This Page

The 13 references the cards above cite, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.

Show the 13 references
  1. 20101. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.
  2. 25593. Buckner JC, Malkin MG, Reed E, et al. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 1999;74(2):137-145. PubMed
  3. 25601. Burzynski SR, Conde AB, Peters A, et al. A retrospective study of antineoplastons A10 and AS2-1 in primary brain tumors. Clin Drug Invest 1999;18(1):1-10.
  4. 25603. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed
  5. 25604. Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249. PubMed
  6. 25610. Burzynski SR, Weaver RA, Lewy RI, et al. Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report. Drugs R D 2004;5(6):315-326. PubMed
  7. 25611. Burzynski SR, Weaver RA, Janicki T, et al. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1. Integr Cancer Ther 2005;4(2):168-177. PubMed
  8. 25619. Burzynski SR, Burzynski B, Mohabbat MO. Toxicology studies on antineoplaston AS2-1 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:25-35.
  9. 25620. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.
  10. 25621. Burzynski SR, Kubove E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up. Drugs Exp Clin Res 1987;13 Suppl 1:1-11.
  11. 25623. Kumabe T, Tsuda H, Uchida M, et al. Antineoplaston treatment for advanced hepatocellular carcinoma. Oncol Rep 1998;5(6):1363-1367. PubMed
  12. 25624. Burzynski SR. Toxicology studies on antineoplaston AS2-5 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:17-24.
  13. 99814. Burzynski SR, Janicki TJ, Weaver RA, Burzynski B. Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integr Cancer Ther. 2006 Mar;5(1):40-7. PubMed

All 20 references behind our Antineoplastons records are listed in the Antineoplastons guide.

Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is reviewed by the HelloPharmacist Editorial Team. See our data sources and editorial standards.

Where Does Our Data Come From?
  • Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
  • Citation library: 105,612 references behind our interaction content, 67,053 of them resolved to verified PubMed/DOI sources. See the references behind this page ↓
  • Freshness: we automatically re-check this combination every week — this pair was last verified November 15, 2026. The Antineoplastons and tipranavir records this page draws on were last updated July 10, 2026.
Data structure & sourcing designed and verified by .
Rating Key

What Our Interaction Ratings Mean

No interaction is on record for this pair. The other supplements and medicines on this page carry a severity rating: how serious an interaction between them is.

See what each severity means

Severity: How Serious Is It?

How clinically significant the interaction is: how much it could affect your health or your treatment.

  • MajorClinically significant. Best to avoid the combination, or use only under close professional supervision.
  • ModerateBe cautious. The combination may call for monitoring, timing changes, or a dose adjustment.
  • MinorLimited clinical concern, but still worth being aware of and mentioning to your pharmacist.
  • No Known InteractionNo documented interaction in our sources.

Still Have a Question About Antineoplastons and tipranavir?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.